Publications by authors named "Alvise Mattana"
Article Synopsis
- There are various first-line treatment options for metastatic renal cell carcinoma (mRCC), with immuno-combination therapies being the standard for all patients, while TKI monotherapy is suitable for some individuals.
- The REGAL study is a multi-center observational research project that will analyze both current and past systemic therapy data in mRCC patients to identify factors that might influence treatment decisions.
- The study also aims to compare the effectiveness and safety of different treatments and to evaluate a new prognostic tool called the Meet-URO score against the established IMDC score.
Introduction: Penile squamous cell carcinoma (PSCC) is a rare tumor with an aggressive behavior. The Meet-URO 23/I-RARE registry includes rare genitourinary malignancies. We extracted patients with PSCC to conduct a retrospective study aimed at assessing clinical outcomes and prognostic factors.
View Article and Find Full Text PDFIntroduction: A low fT3/fT4 ratio has been associated with a poorer prognosis in patients treated for different solid malignancies. However, the prognostic role of baseline thyroid function in patients with metastatic urothelial carcinoma (mUC) has not yet been established.
Patients And Methods: We analyzed 72 consecutive immunotherapy-treated patients with mUC from a single institution.
Introduction: Immunotherapy with nivolumab (a monoclonal antibody that targets the programmed cell death protein 1, PD1) has become the standard treatment for patients with metastatic renal cell carcinoma (mRCC) after progression to single-agent tyrosine kinase inhibitors. However, the optimal duration of immunotherapy in this setting has not yet been established.
Patients And Methods: We retrospectively reviewed all patients treated with nivolumab at our institution from January 2014 to December 2021 and identified those who discontinued treatment for reasons other than disease progression (PD).